{"organizations": [], "uuid": "751a7ed5466394d0a10c8c9a003f30eb15c9df2b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-psivida-announces-acquisition-of-i/brief-psivida-announces-acquisition-of-icon-bioscience-financing-agreements-idUSL8N1RA79K", "country": "US", "domain_rank": 408, "title": "BRIEF-pSivida announces Acquisition Of Icon Bioscience, financing agreements", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-29T00:22:00.000+03:00", "replies_count": 0, "uuid": "751a7ed5466394d0a10c8c9a003f30eb15c9df2b"}, "author": "", "url": "https://www.reuters.com/article/brief-psivida-announces-acquisition-of-i/brief-psivida-announces-acquisition-of-icon-bioscience-financing-agreements-idUSL8N1RA79K", "ord_in_thread": 0, "title": "BRIEF-pSivida announces Acquisition Of Icon Bioscience, financing agreements", "locations": [], "entities": {"persons": [], "locations": [{"name": "psivida", "sentiment": "none"}, {"name": "u.s", "sentiment": "none"}], "organizations": [{"name": "acquisition of icon biosci", "sentiment": "negative"}, {"name": "brief-psivida", "sentiment": "negative"}, {"name": "acquisition of icon bioscience", "sentiment": "negative"}, {"name": "psivida corp", "sentiment": "none"}, {"name": "psivida", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "bioscience inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 28 (Reuters) - pSivida Corp:\n* PSIVIDA CORP. ANNOUNCES TRANSFORMATIVE ACQUISITION OF ICON BIOSCIENCE INC. AND GROWTH CAPITAL FINANCING WITH ESSEX WOODLANDS HEALTHCARE PARTNERS â€“ COMPANY WILL REBRAND AS EYEPOINT PHARMACEUTICALS, INC.\n* EW HEALTHCARE & THIRD PARTY INVESTOR TO MAKE INVESTMENT IN CO OF UP TO ABOUT $60.5 MILLION\n* SWK HOLDINGS WILL PROVIDE UP TO $20 MILLION IN DEBT FINANCING\n* PSIVIDA CORP. WILL REBRAND AND CHANGE ITS NAME TO EYEPOINT PHARMACEUTICALS INC.\n* ENTERED INTO A FINANCIAL AGREEMENT WITH EW HEALTHCARE PARTNERS\n* EW HEALTHCARE PARTNERS AND A THIRD PARTY INVESTOR WILL MAKE EQUITY INVESTMENTS IN PSIVIDA\n* WILL USE FUNDS TO FINANCE ICON ACQUISITION AND PREPARE FOR COMMERCIAL LAUNCHES OF DEXYCU\n* IF APPROVED, PSIVIDA EXPECTS TO LAUNCH DURASERT IN U.S. IN FIRST HALF OF 2019\n* PSIVIDA PLANS TO LAUNCH DEXYCU IN U.S. IN FIRST HALF OF 2019\n* EW HEALTHCARE PARTNERS AND A THIRD PARTY INVESTOR WILL MAKE AN EQUITY INVESTMENT IN PSIVIDA FOR UP TO ABOUT $60.5 MILLION Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-03-29T00:22:00.000+03:00", "crawled": "2018-03-29T00:32:59.000+03:00", "highlightTitle": ""}